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COMMENTARY




Endophthalmitis is an uncommon but often visually devastating complication of intravitreal injections. This com-
mentary reviews the key aspects and technical components of intravitreal injections and how they may relate to the 
development of endophthalmitis. Because endophthalmitis is a rare event, data are often lacking on specific aspects 
of injection technique that may or may not be helpful in preventing infection. What is not in doubt, however, is the 
utmost importance of using povidone-iodine antisepsis to the ocular surface prior to injection, and maintaining a lash 
and lid margin-free injection site.
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Background
Intravitreal injections are routinely performed in a busy 
vitreoretinal clinic. They are generally safe, but their 
feared complication—endophthalmitis—can be a visu-
ally devastating event. Understanding the key steps to 
the injection procedure may help minimize the risk of 
endophthalmitis, and perhaps drive the event rate lower 
than it currently stands. The aim of this Commentary is 
to discuss some of these key steps.
Main text
Intravitreal drug delivery has revolutionized retinal 
care over the past decade, driven largely by the sky-
rocketing use of anti-vascular endothelial growth fac-
tor (anti-VEGF) agents for the treatment of neovascular 
age-related macular degeneration (AMD), retinal vein 
occlusion (RVO), and diabetic macular edema (DME) 
[1]. These injections are generally safe and well-toler-
ated, and effective at stabilizing vision in most patients, 
and improving vision in some patients. One downside 
to these drugs is their relatively short duration of effect; 
patients often need frequent, sometimes monthly, injec-
tions to maintain visual gains. It is not an uncommon 
scene, then, in a busy vitreoretinal clinic, to see patients 
receiving their 20th, 30th or even 40th injection.
One challenge this need for repeat injections leads to is 
an increased likelihood of a patient experiencing a com-
plication of an intravitreal injection over the lifetime of 
their treatment. The most feared complication of intra-
vitreal injection is endophthalmitis, which can be visually 
devastating to the affected eye. The rate of endophthal-
mitis is somewhere between 1 and 2,000–5,000 injec-
tions [2], far less than the 1 in 400 rate of post-operative 
endopthalmitis seen after cataract surgery [3]. However, 
unlike cataract surgery, which a patient experiences 
only one time (per eye), an intravitreal injection is a fre-
quently-repeated process, which can transform a low per 
injection complication rate into a higher per patient com-
plication rate.
Though longer-acting agents may be on the horizon, 
intravitreal injections will likely be a key component of 
retinal care for the foreseeable future. Given this real-
ity, how can we, as vitreoretinal specialists, drive the 
rate of endophthalmitis after intravitreal injection even 
lower? One prerequisite to answering this question is to 
fully understand where we are and what we know now. 
How frequently does infection occur? What are the com-
mon causative organisms? What are the critical steps 
to the procedure? What techniques have been shows to 
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be effective—or not effective—at reducing the risk of 
endophthalmitis?
To this end, Drs. Merani and Hunyor [4] took an 
important step to answer these questions by summariz-
ing and synthesizing the critical data and expert opin-
ions on endophthalmitis after intravitreal injections. 
They limit their literature review to published articles on 
endophthalmitis after intravitreal anti-VEGF injections, 
and exclude data from clinical trials or from those that 
include steroid or other non-anti-VEGF injections. Both 
of these are reasonable decisions. Clinical trials often 
exclude certain patient populations or mandate protocol-
specific injection techniques that may not mimic what 
happens every day in vitreoretinal clinics. Similarly, the 
rate of endophthalmitis after intravitreal steroid injec-
tions has been reported to be higher than that seen 
after intravitreal anti-VEGF injections [5], which may be 
related to the drug, drug vehicle, or patient population 
and disease states requiring steroid injections.
The authors identified 20 papers that met their inclu-
sion criteria, with each case series having at least 10,000 
injections. Over 500,000 injections were pooled, and 144 
cases of endophthalmitis were identified. This leads to a 
rate of 0.028  % [4], which is consistent with previously 
reported rates.
The reported incidence of endophthalmitis appears 
to be marginally lower in an operating room-based set-
ting (a common location for intravitreal injections in 
Europe) versus an office location (where the vast major-
ity of injections occur in the United States) [4]. However, 
these studies were all retrospective in nature, and it can 
be difficult to compare the different series. Additionally, 
the logistical challenges and extensive cost that would be 
required to shift office-based injections to an operating 
room would be impractical, at least in the United States.
Would mimicking the operating room environment in 
the clinic help? In several instances, Merani and Hunyor 
suggest this may be helpful, though without sufficient 
evidence to support their recommendation. For exam-
ple, they suggest that sterile gloves should be worn by 
the treating clinician, though acknowledge no data exist 
as to whether gloves at all—let alone sterile gloves—help 
reduce the rate of endophthalmitis [4]. Similarly, while 
Wen et al. demonstrated some laboratory simulations of 
the effect of talking on bacterial growth [6], the use of 
facemasks specifically, whether worn by the injecting cli-
nician, the technician, or the patient, has not been shown 
to lower the risk of endophathalmitis. Limiting talking 
during the procedure may be sufficient.
No data regarding hand antisepsis exists to support one 
type of hand antisepsis over another, though maintaining 
good hand hygiene, including the use of alcholol-based 
agents before and after patient contact, seems to be a 
good idea. This is the current recommendation for every 
patient encounter, not just for those receiving intravitreal 
injections [7].
The package inserts for both ranibizumab (Lucentis, 
Genentech/Roche, South San Francisco, CA) and afliber-
cept (Eylea, Regeneron, Tarrytown, NY) state that sterile 
gloves, drape, and speculum should be used with each 
injection [8, 9]. Here again, a paucity of useful data is 
available to guide us as to whether these three items can 
help reduce endophthalmitis. Certainly, adequate hand 
hygiene is required, as is sufficient retraction of the lid 
margin from the injection site. The lid speculum is often 
uncomfortable for patients, and manual retraction of the 
lids is often sufficient to achieve the goal of avoiding eye-
lid contact with the intended injection site and needle 
[10].
Merani and Hunyor recommend disinfecting the rub-
ber diaphragm of ranibizumab or aflibercept vials with an 
alcohol swab immediately before drawing up the medi-
cine into the tuberculin syringe [4]. However, if the metal 
cap is removed immediately prior to puncturing the vial, 
with care being taken to avoid touching the rubber dia-
phragm, this step may be unnecessary, or even harmful. 
Numerous instances of contaminated alcohol prep pads 
and swabs have been reported, in some cases leading to 
nationwide recalls [11].
Ultimately, what is not debated is the paramount 
importance of topical antisepsis prior to intravitreal 
injection. For this, povidone iodine solutions are the gold 
standard. Standard surgical skin preparations are typi-
cally 10  % povidone iodine concentration, and include 
detergents that are toxic and irritating to the ocular sur-
face. Betadine (Alcon Laboratories, Fort Worth, Tx) is a 
5 % povidone iodine solution designed for ocular surface 
anti-sespsis. It can still be irritating and uncomfortable to 
the ocular surface, even with a pre-treatment anesthetic 
drop such as proparacaine. It should be applied before 
any viscous anesthetic gels to achieve adequate antisep-
sis. Pre- or post-injection antibiotics do not help prevent 
endophthalmits, and may be harmful by inducing micro-
bial resistance [10].
Conclusion
Given the projected growth of intravitreal injections [1], 
we must continue to search for new and better ways to 
further reduce the rate of endophthalmitis after each 
injection. Doing so may enable us to drive the per patient 
rate of infection lower than where it stands today. Though 
endophthalmitis after intravitreal injection may not be a 
“never event,” [12] we must still strive to do better.
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